Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

David Thomas Scadden, M.D.

Co-Author

This page shows the publications co-authored by David Scadden and Rakesh Jain.
Connection Strength

0.928
  1. Generation of functionally competent and durable engineered blood vessels from human induced pluripotent stem cells. Proc Natl Acad Sci U S A. 2013 Jul 30; 110(31):12774-9.
    View in: PubMed
    Score: 0.140
  2. Differential in vivo potential of endothelial progenitor cells from human umbilical cord blood and adult peripheral blood to form functional long-lasting vessels. Blood. 2008 Feb 01; 111(3):1302-5.
    View in: PubMed
    Score: 0.094
  3. Endothelial cells derived from human embryonic stem cells form durable blood vessels in vivo. Nat Biotechnol. 2007 Mar; 25(3):317-8.
    View in: PubMed
    Score: 0.090
  4. A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood. Nat Protoc. 2007; 2(4):805-10.
    View in: PubMed
    Score: 0.089
  5. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007 Jan; 11(1):83-95.
    View in: PubMed
    Score: 0.089
  6. Differential circulation kinetics during antiangiogenic therapy of four distinct blood cell populations expressing endothelial markers. J Clin Oncol. 2006 Jun 20; 24(18_suppl):3038.
    View in: PubMed
    Score: 0.086
  7. Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. J Clin Oncol. 2006 Mar 20; 24(9):1449-53.
    View in: PubMed
    Score: 0.084
  8. Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. Blood. 2006 Apr 01; 107(7):2774-6.
    View in: PubMed
    Score: 0.083
  9. Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nat Med. 2005 Jun; 11(6):678-82.
    View in: PubMed
    Score: 0.079
  10. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004 Feb; 10(2):145-7.
    View in: PubMed
    Score: 0.073
  11. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol. 2005 Nov 01; 23(31):8136-9.
    View in: PubMed
    Score: 0.021
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.